Ramantamig Trispecific Antibody in Multiple Myeloma: High Response Rates & Mild CRS | IMS 2026

Jeffrey Matous, MD, of Colorado Blood Cancer Institute discusses ramantamig, a first-in-class trispecific antibody, at IMS 2026 in Glasgow. Ramantamig directs T cells to attack two myeloma targets at once, BCMA and GPRC5D. In patients who had not received these immune therapies before, preventive tocilizumab kept cytokine release syndrome mild enough to start treatment in the clinic rather than the hospital. Response rates so far have been very high and durable.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity

Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:

0:00 Introduction

0:18 What is a trispecific antibody?

1:31 Testing it in the clinic instead of the hospital

2:09 What is CRS?

2:42 Safety results

3:17 How well did it work?